- Home
- TDUP vs PRQR Comparison
TDUP vs PRQR Comparison
Compare TDUP & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | PRQR |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 262.5M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TDUP | PRQR |
|---|---|---|
| Price | $1.40 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $7.24 | ★ $7.78 |
| AVG Volume (30 Days) | ★ 1.6M | 938.4K |
| Earning Date | 11-04-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $310,813,000.00 | N/A |
| Revenue This Year | $11.55 | $8.25 |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.53 | N/A |
| 52 Week Low | $1.91 | $1.20 |
| 52 Week High | $8.76 | $2.49 |
Technical Indicators
Market Signals| Indicator | TDUP | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 44.76 |
| Support Level | $2.09 | $1.37 |
| Resistance Level | $2.52 | $1.99 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 57.15 | 70.00 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.